Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $80.2308.

Several brokerages have recently commented on RARE. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 9th. Truist Financial reduced their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. TD Cowen cut their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Barclays reduced their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th.

Ultragenyx Pharmaceutical Trading Down 42.3%

Shares of RARE opened at $19.72 on Thursday. The firm has a fifty day moving average price of $33.66 and a 200-day moving average price of $32.11. The firm has a market capitalization of $1.90 billion, a P/E ratio of -3.32 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12-month low of $18.41 and a 12-month high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The company had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.40) EPS. Analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Howard Horn sold 3,081 shares of the company’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at approximately $3,461,411.48. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 614.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the period. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical in the second quarter valued at approximately $35,765,000. Adage Capital Partners GP L.L.C. increased its holdings in Ultragenyx Pharmaceutical by 81.6% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock worth $77,815,000 after buying an additional 965,919 shares during the period. Assenagon Asset Management S.A. raised its position in Ultragenyx Pharmaceutical by 439.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock worth $42,314,000 after buying an additional 947,865 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $22,560,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: There are reports characterizing the Phase 3 readout as “mixed,” noting that while the primary endpoints were missed there may be secondary/exploratory signals or an acceptable safety profile that could support further analyses or alternative paths forward. Article Title
• Neutral Sentiment: Trading in RARE was temporarily halted (08:25 AM) for a company announcement and Ultragenyx posted an official press release with the Phase 3 Orbit and Cosmic results — investors should review the full release and any forthcoming company commentary for details and planned next steps. Article Title
• Negative Sentiment: Both Phase 3 trials (Orbit and Cosmic) failed to meet their primary endpoint — no statistically significant reduction in annualized clinical fracture rate versus placebo (Orbit) or versus bisphosphonates (Cosmic) — eliminating the core efficacy case for setrusumab in OI. Article Title
• Negative Sentiment: The market reacted violently: RARE plunged on the news and reports say the failure wiped more than $1 billion from the company’s market value. Expect continued elevated volume, volatility and possible analyst downgrades. Article Title
• Negative Sentiment: Management signaled “significant” cutbacks in response to the trial failures, which suggests program reductions, cost cuts and possible reprioritization of R&D spending — a near-term negative for growth expectations. Article Title
• Negative Sentiment: The failed program was a high-profile asset (developed with/related to Mereo in coverage), so the setback has broader implications for partnerships, future catalysts and revenue potential tied to bone-disease programs. Article Title

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.